|The full article is available to subscribers||Subscriber Login|
The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate. Utibron Neohaler (Novartis) contains both glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a long-acting anticholinergic and a LABA to become available in the US; umeclidinium/vilanterol (Anoro Ellipta)1 and tiotropium/olodaterol (Stiolto Respimat)2 were approved earlier.
GLYCOPYRROLATE — Glycopyrrolate has been available for many years in a parenteral formulation for multiple indications. An oral formulation is available for reduction of chronic severe drooling in children with certain... more
- Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD. Med Lett Drugs Ther 2014; 56:30.
- Tiotropium/olodaterol (Stiolto Respimat) for COPD. Med Lett Drugs Ther 2015; 57:161.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. Available at www.goldcopd.org. Accessed March 17, 2016.
- Drugs for asthma and COPD. Treat Guidel Med Lett 2013; 11:75.
- DA Mahler et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192:1068.